In early November, HistoGeneX pathologists published a paper in Nature Medicine, in collaboration with researchers from Barts Cancer Institute, Queen Mary University of London.

More

We are delighted to announce that HistoGeneX will start a histopathology biomarker laboratory in China. This update is the first issue of our Chinese journey. We will provide our progress via this communication. Please include us in your global clinical trial planning and send us your questions.

More

The HistoGeneX molecular team performs more than 11,000 DNA and RNA extractions each year manually. Yes, manually.

More

Neo-adjuvant immunotherapy in bladder cancer. Complete pathological response in bladder wall is related with the PDL1 status and opens opportunities to understand biological mechanism of action.

More